Wong, Chun Wai https://orcid.org/0000-0002-5902-4571
Evangelou, Christos https://orcid.org/0000-0002-1618-9448
Sefton, Kieran N.
Leshem, Rotem https://orcid.org/0000-0002-8916-9843
Zhang, Wei https://orcid.org/0000-0002-3826-7128
Gopalan, Vishaka
Chattrakarn, Sorayut https://orcid.org/0000-0002-6880-3550
Fernandez Carro, Macarena Lucia https://orcid.org/0000-0002-0196-0711
Uzuner, Erez https://orcid.org/0000-0003-0341-9221
Mole, Holly
Wilcock, Daniel J. https://orcid.org/0000-0002-3183-5540
Smith, Michael P. https://orcid.org/0000-0002-5980-7840
Sergiou, Kleita
Telfer, Brian A. https://orcid.org/0000-0003-1857-5120
Isaac, Dervla T. https://orcid.org/0009-0000-6165-345X
Liu, Chang
Perl, Nicholas R.
Marie, Kerrie https://orcid.org/0000-0002-2860-918X
Lorigan, Paul https://orcid.org/0000-0002-8875-2164
Williams, Kaye J. https://orcid.org/0000-0001-7708-3770
Rao, Patricia E.
Nagaraju, Raghavendar T. https://orcid.org/0000-0002-6891-5181
Niepel, Mario https://orcid.org/0000-0003-1415-6295
Hurlstone, Adam F. L. https://orcid.org/0000-0001-5260-9457
Funding for this research was provided by:
Melanoma Research Alliance (821034)
Worldwide Cancer Research (22-0091)
Skin Cancer Foundation
Skin Cancer Research Fund Melanoma UK
Hong Kong Scholarship for Excellence Scheme
RCUK | Medical Research Council
Christie Charity
Article History
Received: 25 November 2022
Accepted: 18 September 2023
First Online: 26 September 2023
Competing interests
: The authors declare the following competing interests: D.T.I., C.L., N.R.P. and M.N are all employees and shareholders of Ribon Therapeutics at the time of data collection. P.E.R. served as a consultant to Ribon Therapeutics. A.H. received research sponsorship from Ribon Therapeutics. All other authors declare no competing interests.